ECHELON-2试验中PET4缓解与BV-CHP对比CHOP治疗CD30阳性外周T细胞淋巴瘤结局的关联
该研究为ECHELON-2的探索性事后分析,评估第4周期后PET(PET4)缓解与无进展生存期(PFS)和总生存期(OS)的关联。452例患者随机1:1接受BV-CHP(n=226)或CHOP(n=226)。两臂中PET4阴性均与改善的PFS和OS相关。
要点
- PET4阴性(Deauville评分1-3分)在BV-CHP和CHOP两臂均与改善的PFS和OS相关。
- 系统性间变性大细胞淋巴瘤患者中,PET4阴性同样与改善的PFS和OS相关。
- 该分析为ECHELON-2的探索性事后分析。
核心结论
- 在该探索性分析中,按Deauville评分判定的PET4阴性状态在BV-CHP和CHOP两臂均与改善的长期PFS和OS相关。
研究设计与样本
- 该研究为3期ECHELON-2试验的探索性事后分析,评估第4周期后18F-氟脱氧葡萄糖PET(PET4)及基于治疗结束的缓解,并与研究者评估的PFS和OS进行相关性分析。
- PET4缓解由独立审查按Deauville评分判定:1-3分为阴性(PET4阴性),4-5分为阳性(PET4阳性)。
- 共452例患者随机1:1分配至BV-CHP(n=226)和CHOP(n=226)臂;其中BV-CHP臂32例、CHOP臂41例无法评估PET4。
主要发现
- 两臂中,PET4阴性状态与PET4阳性状态相比,PFS改善:BV-CHP臂HR为0.36(95%CI 0.19-0.66),CHOP臂HR为0.26(95%CI 0.17-0.41)。
- 两臂中,PET4阴性状态与PET4阳性状态相比,OS改善:BV-CHP臂HR为0.38(95%CI 0.18-0.78),CHOP臂HR为0.24(95%CI 0.14-0.41)。
- 在系统性间变性大细胞淋巴瘤患者中,PET4阴性患者与PET4阳性患者相比,PFS改善:BV-CHP臂HR为0.28(95%CI 0.14-0.60),CHOP臂HR为0.31(95%CI 0.17-0.56)。
- 在系统性间变性大细胞淋巴瘤患者中,PET4阴性患者与PET4阳性患者相比,OS改善:BV-CHP臂HR为0.38(95%CI 0.16-0.94),CHOP臂HR为0.25(95%CI 0.12-0.55)。
局限性
- 该分析为探索性事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the phase 3 ECHELON-2 trial, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (BV-CHP) significantly improved progression-free survival (PFS) and overall survival (OS) compared with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with CD30+ peripheral T-cell lymphoma, benefits that were maintained at 5 years. Interim positron emission tomography (PET) scan can be used to assess prognosis and risk-stratify patients. The prognostic value of interim PET was assessed in this post hoc exploratory analysis from ECHELON-2, evaluating interim 18F-fluorodeoxyglucose PET scans after cycle 4 (PET4) and end-of-treatment-based response, and correlated with PFS per investigator and OS. PET4 response was determined by Deauville score (scores of 1-3 were considered negative [PET4-negative] and 4-5 positive [PET4-positive]) by independent review. Overall, 452 patients were randomized 1:1 to the BV-CHP (n = 226) and CHOP (n = 226) arms. Of these, 32 in the BV-CHP arm and 41 in the CHOP arm were not evaluable for PET4. In both arms, PET4-negative status was associated with improved PFS (BV-CHP: HR, 0.36; 95% CI, 0.19-0.66; CHOP: HR, 0.26; 95% CI, 0.17-0.41) and OS (BV-CHP: HR, 0.38; 95% CI, 0.18-0.78; CHOP: HR, 0.24; 95% CI, 0.14-0.41) compared with PET4-positive status. Among patients with systemic anaplastic large cell lymphoma, PET4-negative patients had improved PFS (BV-CHP: HR, 0.28; 95% CI, 0.14-0.60; CHOP: HR, 0.31; 95% CI, 0.17-0.56) and OS (BV-CHP: HR, 0.38; 95% CI, 0.16-0.94; CHOP: HR, 0.25; 95% CI, 0.12-0.55) compared with PET4-positive patients. In this exploratory analysis, PET4-negative status by Deauville score was associated with improved long-term PFS and OS in both the BV-CHP and CHOP arms. This trial was registered at www.ClinicalTrials.gov as #NCT01777152.
引用
- Iyer S, Mehta-Shah N, Advani R, et al. Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma. Blood Adv. 2025. PMID: 40829107. doi:10.1182/bloodadvances.2024015282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。